BCL2 and cancer: ABT-737, a Bad-like BH3 mimetic which selectively bounds to Bcl-2, Bcl-XL and Bcl-w, is highlighted as a promising anti-cancer agent, meanwhile, its low affinity with Mcl-1 and high basal level of Mcl-1 expression in cancer cells is preventing it from being efficient as a single agent.